Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 82% Improvement Relative Risk Symptomatic case (b) 88% Case 29% c19hcq.org Raabe et al. NCT04354870 HCQ PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 130 patients in the USA Fewer symptomatic cases with HCQ (not stat. sig., p=0.17) Raabe et al., medRxiv, doi:10.1101/2022.07.01.22277058 Favors HCQ Favors control
Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial
Raabe et al., medRxiv, doi:10.1101/2022.07.01.22277058 (Preprint), NCT04354870 (history)
Raabe et al., Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for.., medRxiv, doi:10.1101/2022.07.01.22277058 (Preprint), NCT04354870
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small prophylaxis study with 130 healthcare workers in the USA, showing lower symptomatic cases with HCQ prophylaxis, without statistical significance. HCQ participants were significantly older. The only symptomatic HCQ patient reported headache only as a potential COVID-19 symptom.
risk of symptomatic case, 82.2% lower, RR 0.18, p = 0.17, treatment 1 of 59 (1.7%), control 2 of 21 (9.5%), NNT 13.
risk of symptomatic case, 88.4% lower, RR 0.12, p = 0.07, treatment 0 of 59 (0.0%), control 2 of 21 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), fever.
risk of case, 28.8% lower, RR 0.71, p = 0.65, treatment 4 of 59 (6.8%), control 2 of 21 (9.5%), NNT 36, seroconversion.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Raabe et al., 3 Jul 2022, prospective, USA, preprint, 7 authors, trial NCT04354870 (history).
Contact: vanessa.raabe@nyulangone.org.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.01.22277058; this version posted July 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Title: Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among 2 health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial 3 Running Title: Hydroxychloroquine pre-exposure prophylaxis for SARS-CoV-2 4 5 Authors: Vanessa N. Raabe, MD1; Andrew Fleming, MD1,2; Marie I. Samanovic, Ph. D1; Lilin 6 Lai, MD1,3; Hayley M. Belli, Ph. D4; Mark J. Mulligan, MD1; H. Michael Belmont, MD5 7 8 Affiliations: 9 1 Division of Infectious Diseases & Immunology and NYU Langone Vaccine Center, Department 10 of Medicine, New York University Grossman School of Medicine 11 2 12 New York University Long Island School of Medicine 13 3 Current affiliation: Emory Vaccine Center, Emory University School of Medicine 14 4 Division of Biostatistics, Department of Population Health, New York University Grossman 15 School of Medicine 16 5 17 School of Medicine Current affiliation: Division of Infectious Diseases & Immunology, Department of Medicine, Department of Rheumatology, Department of Medicine, New York University Grossman 18 19 Corresponding Author: Vanessa Raabe, 430 E 29th St., Alexandria Center for Life Sciences West 20 Tower, 3rd Floor, New York, NY 10016. Vanessa.Raabe@nyulangone.org 21 22 World Count: Abstract – 274; Text - 3041 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.07.01.22277058; this version posted July 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 23 Abstract: 24 Background: Aerosol-generating procedures increase the risk of severe acute respiratory 25 syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs). An 26 effective pre-exposure prophylaxis would mitigate this risk. 27 28 Objective: To determine the efficacy of pre-exposure prophylactic hydroxychloroquine for the 29 prevention of SARS-CoV-2 infection and symptomatic coronavirus 19 disease (COVID-19) 30 among HCWs at high occupational risk of SARS-CoV-2 exposure. 31 32 Methods: 130 HCWs in the New York University Langone Health System (NYULHS) who 33 performed aerosol-generating procedures on patients with COVID-19 or provided bedside care 34 for inpatients with COVID-19 or persons with suspected COVID-19 in an emergency 35 department, for at least three shifts in a 7-day period, during the first 2020 COVID-19 wave in 36 New York City were enrolled. Participants elected to take oral hydroxychloroquine, 600 mg on 37 day 1 followed by 200 mg daily, or not take hydroxychloroquine for up to 90 days. Participants 38 self-collected dried blood spots and completed digital questionnaires regarding COVID-19 39 symptoms, adverse events, and other COVID-19 medication use. 40 41 Results: Six participants (7.5%) seroconverted during the trial: four who took 42 hydroxychloroquine..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit